Erythropoietin

(redirected from Erythropoietins)
Also found in: Dictionary, Thesaurus, Medical.
Related to Erythropoietins: Hemopoietin, erythropoietin stimulating factor

erythropoietin

[ə‚rith·rə′pȯi·ət·ən]
(biochemistry)
A hormone, thought to be produced by the kidneys, that regulates erythropoiesis, at least in higher vertebrates.

Erythropoietin

 

a hormone that stimulates the formation of erythrocytes in bone marrow. Characterized as a glycoprotein, erythropoietin has a carbohydrate content of 35 percent. It has a molecular weight of 30,000–40,000 and possesses antigenic properties. Erythropoietin is inactivated by neuraminidase, trypsin, chymotrypsin, and papain.

Erythropoietin was discovered by the French researchers F. Corneau and C. de Flandre in 1906 in rabbit serum that they tested after drawing blood. The hormone is found in low concentrations under normal physiological conditions, but the levels increase when the subject is in a state of hypoxia as a result of the loss of blood, a decrease in the oxygen content of the air, or various forms of anemia. Most scientists believe that erythropoietin is formed in the kidneys. When the hormone acts on stem cells in bone marrow, it causes their differentiation into cells of the erythroid series.

REFERENCES

Fedorov, N. A., and M. G. Kakhetelidze. Eritropoetin. Moscow, 1973.
Normal’noe krovetvorenie i ego reguliatsiia. Moscow, 1976.
Gordon, A. S. Regulation of Hematopoiesis, vol. 1. New York [1970].

N. A. FEDOROV

References in periodicals archive ?
Androgens, although potentially effective in increasing production of erythropoietin, historically played a small role in the management of anemia of ESRD prior to the introduction of ESAs.
Erythropoietin and Its Relationship With the Erythrpoietin Receptor
Erythropoietin is the key hormone responsible for governing RBC development.
Jacobs Immunological reaction against erythropoietin causing red-cell aplasia
Autoantibodies against erythropoietin in a patient with pure red cell aplasia.
A case of antierythropoietin antibodies following recombinant human erythropoietin treatment.
Table 11: World Recent Past, Current & Future Analysis for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-65
Table 13: World Long-term Projections for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-67
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
Development of radioimmunoassays for human erythropoietin using recombinant erythropoietin as tracer and immunogen.
Post-receptor (intracellular) effects of erythropoietin
Traumatic brain injury and the potential protective effect of erythropoietin